Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. (Q38205079)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24739325%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

title

Treat-to-target in systemic lupus erythematosus: recommendations from an international task force (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24739325%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

1 reference

systemic lupus erythematosus

1 reference

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24739325%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

David A. Isenberg

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24739325%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Martin Aringer

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24739325%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Ricard Cervera i Segura

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24739325%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Caroline Gordon

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24739325%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Winfried B. Graninger

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24739325%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Søren Jacobsen

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24739325%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Adrian Levitsky

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24739325%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Roger Levy

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24739325%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Eric F. Morand

27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24739325%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Anne Voss

35

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24739325%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

32

Josef Smolen

0 references

Xavier Mariette

26

object named as

Xavier Mariette

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24739325%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

author name string

Marta Mosca

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24739325%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

George Bertsias

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24739325%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Annegret Kuhn

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24739325%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Kirsten Lerstrøm

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24739325%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Hendrika Bootsma

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24739325%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Dimitrios Boumpas

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24739325%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Ann Clarke

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24739325%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

László Czirják

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24739325%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Thomas Dörner

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24739325%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Frédéric Houssiau

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24739325%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Murat Inanc

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24739325%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

David Jayne

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24739325%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Anna Jedryka-Goral

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24739325%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Sandra Navarra

28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24739325%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Irmgard Neumann

29

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24739325%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Anisur Rahman

30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24739325%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Jozef Rovensky

31

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24739325%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Alexandre Voskuyl

34

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24739325%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Helena Zakharova

36

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24739325%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Asad Zoma

37

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24739325%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Matthias Schneider

38

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24739325%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Ronald F van Vollenhoven

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24739325%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Nathalie Costedoat-Chalumeau

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24739325%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Ronald Derksen

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24739325%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Josef Smolen

32

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24739325%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Carlos Vasconcelos

33

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24739325%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

language of work or name

English

0 references

publication date

16 April 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24739325%20AND%20SRC:MED&resulttype=core&format=json

Annals of the Rheumatic Diseases

14 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24739325%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

volume

73

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24739325%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24739325%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

page(s)

958-967

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24739325%20AND%20SRC:MED&resulttype=core&format=json

Pharmacological treatment of hypertension

14 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-205139

Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-205139

Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial)

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-205139

Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-205139

Treating rheumatoid arthritis to target: recommendations of an international task force

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-205139

Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-205139

Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-205139

European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-205139

The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-205139

Predictors of organ damage in systemic lupus erythematosus: the Hopkins Lupus Cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-205139

Accelerated damage accrual among men with systemic lupus erythematosus: XLIV. Results from a multiethnic US cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-205139

Lupus disease activity and the risk of subsequent organ damage and mortality in a large lupus cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-205139

Systemic lupus erythematosus in a multiethnic US cohort LUMINA LI: anaemia as a predictor of disease activity and damage accrual.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-205139

Analysis of the relationship between disease activity and damage in patients with systemic lupus erythematosus--a 5-yr prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-205139

Seizures in patients with systemic lupus erythematosus: data from LUMINA, a multiethnic cohort (LUMINA LIV).

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-205139

Definition of risk factors for death, end stage renal disease, and thromboembolic events in a monocentric cohort of 338 patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-205139

Association between serum total cholesterol level and renal outcome in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-205139

Remission of systematic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-205139

Disease activity and damage accrual during the early disease course in a multinational inception cohort of patients with systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-205139

Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-205139

Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-205139

Membranous nephropathy in systemic lupus erythematosus: long-term outcome and prognostic factors of 103 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-205139

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-205139

The BILAG multi-centre open randomized controlled trial comparing ciclosporin vs azathioprine in patients with severe SLE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-205139

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-205139

Mycophenolate versus Azathioprine as Maintenance Therapy for Lupus Nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-205139

Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-205139

Renal flares in 91 SLE patients with diffuse proliferative glomerulonephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-205139

Distinct subtypes of myelitis in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-205139

Systemic lupus erythematosus. I. Outcome and survival: Dutch experience with 110 patients studied prospectively

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-205139

Relationship between damage accrual, disease flares and cumulative drug therapies in juvenile-onset systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-205139

SLE disease patterns in a Danish population-based lupus cohort: an 8-year prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-205139

A decrease in complement is associated with increased renal and hematologic activity in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-205139

Decreases in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-205139

Prevalence of flare and influence of demographic and serologic factors on flare risk in systemic lupus erythematosus: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-205139

Predictive value of complement profiles and anti-dsDNA in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-205139

Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-205139

Association of antinucleosome antibodies with disease flare in serologically active clinically quiescent patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-205139

The complex nature of serum C3 and C4 as biomarkers of lupus renal flare.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-205139

Outcomes in patients with systemic lupus erythematosus with and without a prolonged serologically active clinically quiescent period

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-205139

Damage and mortality in a group of British patients with systemic lupus erythematosus followed up for over 10 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-205139

Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-205139

Time to seizure occurrence and damage in PROFILE, a multi-ethnic systemic lupus erythematosus cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-205139

Top 10 recent developments in health-related quality of life in patients with systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-205139

Quality-of-life measurements versus disease activity in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-205139

Lupus-specific health outcome measure for US patients: the LupusQoL-US version.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-205139

The LupusQoL and associations with demographics and clinical measurements in patients with systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-205139

Relationship between flare and health-related quality of life in patients with systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-205139

Psychometric properties of the EuroQol-5D and Short Form-6D in patients with systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-205139

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-205139

Brief index of lupus damage: a patient-reported measure of damage in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-205139

The relationship between renal activity and quality of life in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-205139

Effect of disease activity and damage on quality of life in patients with systemic lupus erythematosus: a 2-year prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-205139

Relationship between health-related quality of life and SLE activity and damage in children over time.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-205139

Improvement in health-related quality of life in systemic lupus erythematosus patients enrolled in a randomized clinical trial comparing LJP 394 treatment with placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-205139

Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-205139

Long-term mortality and renal outcome in a cohort of 100 patients with lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-205139

Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-205139

The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-205139

Prednisone, lupus activity, and permanent organ damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-205139

A longitudinal PRINTO study on growth and puberty in juvenile systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-205139

Adverse events during longterm low-dose glucocorticoid treatment of polymyalgia rheumatica: a retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-205139

Incident Comorbidity Among Patients with Rheumatoid Arthritis Treated or Not with Low-dose Glucocorticoids: A Retrospective Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-205139

Antiphospholipid antibodies predict early damage in patients with systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-205139

Analysis of risk factors for the development of thrombotic complications in antiphospholipid antibody positive lupus patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-205139

Antiphospholipid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-205139

Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-205139

A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-205139

A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-205139

Clinical manifestations and outcomes of antithrombotic treatment of the Tan Tock Seng Hospital Singapore antiphospholipid syndrome cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-205139

Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-205139

A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-205139

Double-blind, randomized, controlled clinical trial of clofazimine compared with chloroquine in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-205139

Treatment of lupus skin involvement with quinacrine and hydroxychloroquine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-205139

Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-205139

Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-205139

Changing patterns in mortality and disease outcomes for patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-205139

Predictors of survival in Chinese patients with lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-205139

Angiotensin-converting enzyme inhibitors delay the occurrence of renal involvement and are associated with a decreased risk of disease activity in patients with systemic lupus erythematosus--results from LUMINA (LIX): a multiethnic US cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-205139

Predictors of cognitive dysfunction in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-205139

Peripheral vascular damage in systemic lupus erythematosus: data from LUMINA, a large multi-ethnic U.S. cohort (LXIX)

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-205139

Effect of fluvastatin on cardiac outcomes in kidney transplant patients with systemic lupus erythematosus: a randomized placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-205139

Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-205139

Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-205139

10.1136/ANNRHEUMDIS-2013-205139

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24739325%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

1 reference